AstraZeneca punts NASH drug from an ailing Regulus as their lead program goes under for the last time
The drumbeat of bad news at Regulus is continuing with a rapid tempo today.
Not surprisingly, Regulus has opted to kill off its lead RNAi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
